Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

August 3, 2023

NASDAQ US Health Care Biotechnology earnings 48 min

Earnings Call Speaker Segments

Chris Taylor

executive
#1

Operator, thank you. Good morning, everyone, and hello. It's a pleasure to have all of you with us for the Agios call covering the second quarter of 2023. Today's presentation slides are available on our website, Agios.com, under the investors section. With me today are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, who serves as Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer. Prior to getting started, please note that certain remarks made during this call will contain forward-looking statements. There's a chance that real outcomes and figures won't line up with what any forward-looking statements suggest, because of dangers, unknowns, and additional elements — among them the ones described in the latest documents we've submitted to the SEC, plus any later filings we might submit there. Having said that, I'll hand things over to Brian.

Brian Goff

executive
#2

Appreciate it, Chris. Morning, everybody, and thanks for being with us. Agios exists to bring transformative therapies to people battling rare diseases, and specifically, we're the trailblazing frontrunner when it comes to PK activation aimed at blood-related conditions; during Q2, we achieved meaningful momentum in moving forward our best-in-class pipeline of PK activators that target hematologic diseases sharing one common underlying pathophysiology. Every advance we make, every set of data we report, boosts the likelihood that this platform will succeed, and we're thrilled to walk you through today's updates. As we laid out at the start of 2020's opening months, we're putting priority on possible business development chances judged against five essential criteria: a rare disease orientation, transformative benefit for patients, a defined regulatory route, the ability to reduce risk early on, and an obvious pathway toward creating value. This morning, we were delighted to reveal a licensing deal with Alnylam Pharmaceuticals, the top RNAi therapeutics firm, which fits those five criteria extremely well. Through this arrangement, Agios gains the rights to develop and commercialize Alnylam's innovative preclinical siRNA as a possible therapy for polycythemia vera, or PV. PV is an uncommon and potentially deadly blood disorder impacting roughly 100,000 patients across the U.S., where phlebotomy serves as the standard of care. Our aim is to tackle the substantial unmet need in PV by providing a convenient, disease-modifying option that cuts down or removes the requirement for phlebotomy. So this deal lines up not just with our business development approach, but also with our fundamental scientific know-how and our clinical and commercial strengths in rare hematology; we're eager to kick off IND-enabling studies before this year ends. Sarah will go into further depth about the siRNA development candidate in just a few minutes. The trial hit its primary endpoint of hemoglobin response among patients in both mitapivat treatment arms, and over recent weeks, our team has kept examining the findings and has chosen the 100-milligram dose for the phase III segment of the study; we're now concentrated on phase III execution and are very keen to enroll our first patient before this year is out. More broadly, these findings contribute to the expanding collection of consistent and persuasive data we've kept producing with our PK activators, underscoring how this differentiated mechanism of action could transform patient function, quality of life, and long-term outcomes across numerous disease areas; indeed, with over 8 years of clinical experience and the biggest data set of any PK activator, PYRUKYND has shown consistent results across three separate diseases. Against that backdrop, we were likewise happy to report this quarter that enrollment is now complete in both phase III studies of mitapivat in thalassemia, plus the phase IIa study of our novel PK activator, AG-946, in lower-risk MDS. This headway speaks to our operational excellence in clinical development and the enthusiasm investigators feel about what PK activation might achieve in these indications. Given the progress we've made, our expectation remains that two readouts will come from the phase III ENERGIZE and ENERGIZE-T studies in thalassemia during the coming year, and for the phase IIa trial in lower risk MDS, we have moved the anticipated top-line results forward to the close of this year. Shifting to our commercial side, it's encouraging that the steady, compelling efficacy of mitapivat seen in clinical trials has carried over into real-world persistence on therapy for adults who are living with PK deficiency. While we keep working to get the most out of the current PK deficiency launch, we are also putting the capabilities in place to capture the full potential of future launches we anticipate in thalassemia, sickle cell disease, and lower risk MDS. A thorough commercial performance update will come from Tsveta in just a few minutes. Cecilia will tell you that we closed the second quarter with a cash position of almost $950 million on the balance sheet. One quick note: when we divested our oncology business to Servier in 2021, we kept the rights to a potential $200 million milestone tied to FDA approval of vorasidenib, plus royalties on potential U.S. net sales. Servier's phase III trial results encouraged us, and we're eager to follow what happens next. By year-end, we anticipate several additional milestones, among them enrolling over half of the patients in the phase III ACTIVATE-Kids and ACTIVATE-KidsT studies of mitapivat in pediatric PK deficiency, submitting the IND for our PAH stabilizer to treat PKU, and the newly added milestone, the data readout from the phase IIa study of AG-946 in lower risk MDS. We feel a great deal of enthusiasm about the clinical development momentum we are generating, and we look forward to the anticipated readouts from the phase III mitapivat and thalassemia studies in 2024, along with readouts from the phase III mitapivat studies in sickle cell disease and pediatric PK deficiency in 2025. With that, I'll hand the call over to Sarah.

Sarah Gheuens

executive
#3

Appreciate that, Brian. Sickle cell disease is a severe hematologic condition that can be fatal, and it impacts roughly 120,000 to 135,000 patients across the U.S. and EU5. As of today, no novel oral treatment options exist that simultaneously improve anemia and lower sickle cell pain crises — that's the goal we're pursuing for these patients. Moving to the top-line results from the phase II RISE-UP study, mitapivat treatment showed a statistically significant rise in hemoglobin response rate versus placebo. Hemoglobin response was characterized as a gain of one gram per deciliter or more in average hemoglobin concentrations from week 10 through week 12, relative to baseline. In the 50 milligram BID mitapivat arm, 46.2% of patients achieved a hemoglobin response, and in the 100 milligram BID mitapivat arm, 50% did, versus 3.7% of patients on placebo. Alongside these hemoglobin response increases came improvements in markers of hemolysis and erythropoiesis, plus numerical reductions in the analyzed rate of sickle cell pain crisis over this 12-week study. To be specific, the placebo arm had an analyzed sickle cell pain crisis rate of 1.71, while the 50 milligram arm had 0.83 and the 100 milligram treatment arm had 0.51. Mitapivat's safety profile in this study was generally in line with prior data reported for mitapivat in other trials involving sickle cell disease and other hemolytic anemia. No adverse events resulted in discontinuation in any study arm. Last, out of 79 patients enrolled, 73 carried on into the phase II open label extension period. These findings further highlight mitapivat's potential to tackle the substantial unmet need among sickle cell disease patients by providing a novel oral treatment option that both improves anemia and reduces sickle cell pain crisis. We're eager to share a complete analysis of the phase II data and have submitted an abstract for ASH later this year. Given our ongoing analysis of the compelling data seen at both doses in recent weeks, we've chosen the 100 milligram dose for phase III. As a reminder, the phase III portion of RISE UP will feature a 52-week placebo-controlled period in which 198 patients will be randomized two to one to either mitapivat or placebo twice daily. Hemoglobin response and analyzed rate of sickle cell pain crisis serve as the primary endpoints, and we look forward to enrolling the first patients in the phase III portion of the RISE UP study during the fourth quarter of this year. Shifting to our broader development pipeline, we've been quite pleased with enrollment pace across our programs during the first half of the year. We've finished enrollment in both phase III studies of mitapivat and thalassemia, including ENERGIZE, which enrolled patients who are not regularly transfused with a primary endpoint of hemoglobin response, and ENERGIZE-T, which enrolled patients who are regularly transfused with a primary endpoint of transfusion reduction response. Taken as a whole, these trials are going to produce information that pertains to the thalassemia population in its entirety, which means we can assess how well mitapivat might work as the very first pill-based treatment capable of bettering hemolytic anemia along with ineffective erythropoiesis in every thalassemia subtype. We are eager for the ENERGIZE study readout during the opening six months of next year, plus the ENERGIZE-T readout in the latter six months of next year; another thing that made us happy was finishing enrollment for the phase IIa trial of AG-946 in lower-risk MDS during this quarter, which happened a number of months earlier than planned. AG-946 is a new PK activator that could bolster our PK activator franchise. Top-line findings from the phase IIa trial of AG-946 in lower risk MDS are now anticipated before this year ends, which makes it our upcoming clinical data readout. Just a quick note of context, the main goal of this trial is to demonstrate proof of concept for AG-946 among participants who have lower risk MDS by way of measuring these primary endpoints: hemoglobin response, meaning a rise of at least 1.5 grams per deciliter from baseline in the average hemoglobin concentration spanning week eight to week 16, and transfusion independence, meaning no transfusions for a minimum of eight consecutive weeks while in the study, and only for participants whose transfusion burden is low. At the same time, we keep moving forward the phase III ACTIVATE-Kids and ACTIVATE-KidsT trials of mitapivat in pediatric PK deficiency, and keep working toward submitting the IND for our small molecule PAH stabilizer, which aims straight at the root cause of phenylketonuria, or PKU. Last of all, as Brian noted, we feel good about the agreement announced this morning with Alnylam, an RNAi therapeutics pioneer possessing a best-in-class platform. Polycythemia vera is an uncommon blood disorder that fits neatly with the expertise we hold internally. PV is marked by too much red blood cell production, causing blood volume and viscosity to rise, and that can bring about thrombosis, cardiovascular events, and death. The siRNA development candidate goes after TMPRSS6, a primary force behind red blood cell production. Knocking down TMPRSS6 raises hepcidin while lowering red blood cell production. We are eager to start IND-enabling studies before this year is out and to apply our substantial rare hematology know-how as this program moves toward the clinic. That said, I will hand the call over to Tsveta now.

Tsveta Milanova

executive
#4

Thank you, Sarah. Within our commercial team, the priority stays on capturing as much value as possible from the ongoing PK deficiency launch, which we intend to do by carrying out our plan at every stage of the patient journey. The skills we are developing right now around raising disease awareness and providing education, enabling access and treatment initiation, and supporting adherence and persistence will likewise act as a base for unlocking the full promise of the launches we expect in thalassemia, sickle cell disease, and low-risk MDS. Findings from our market research keep showing that almost 100% of the healthcare providers we target would probably recommend PYRUKYND for their adult patients who have PK deficiency; among clinicians, the main reasons behind those recommendations are better hemoglobin levels, fewer transfusions, and a favorable effect on long-term disease complications. To gain a clearer picture of the treatment experience with PYRUKYND, we recently interviewed a sample of patients or their caregivers. The majority of patients described positive experiences, among them gains in hemoglobin and energy levels, less fatigue, and a lighter transfusion burden. Notably, what we hear from patients and clinicians alike lines up with the robust persistency of treatment use that we saw in the real world following the initial payer reauthorization. On top of that, discontinuations have stayed low, and reauthorizations have not stood in the way. During the second quarter of 2023, net PYRUKYND revenue came to $6.7 million, which is 20% higher than Q1 this year. Altogether, 147 patients have completed a prescription enrollment form, or PES, by now, among them 20 during the second quarter of 2023, marking a 16% rise compared with the first quarter of 2023. That has converted into a net total of 99 patients on therapy, up 11% from last quarter. The patients receiving therapy keep coming from a growing and varied prescriber base made up of 130 physicians, and they span a wide demographic and disease manifestation range that matches the adult PKD deficiency population. Because this disease is ultra-rare, our expectation remains that uptake will be slow and steady. At this early point, we are still concentrating on finding providers who are likely to treat adults with PK deficiency. Our work revolves around applying data and analytics to sharpen physician targeting, since we think a substantial number of potential prescribers may already be managing adult PKD patients; we also keep enhancing efficiency and impact, educating the physicians who do the treating, and creating a sense of urgency about the advantages of diagnosis and suitable treatment. Through those actions, we will help unlock the greatest possible value from the current launch and set the stage for possible launches in considerably larger patient populations. The earliest of those possible launches arrives in 2025 in thalassemia, a setting where roughly 60% of thalassemia patients in the U.S. lack an approved treatment option. This next slide shows how thalassemia subtypes break down in the U.S., covering alpha and beta thalassemia, along with transfusion-dependent and non-transfusion-dependent thalassemia... Crucially, mitapivat could become the first oral therapy capable of improving hemolytic anemia and ineffective erythropoiesis across the entire spectrum of thalassemia patients. Because the various thalassemia subtypes differ in how common they are and in their competitive dynamics, we're eager to roll out a commercial approach tailored to fit, drawing on the capabilities we've built through the launch now underway. Taken as a whole, patients across all thalassemia types number roughly 18,000 to 23,000 in the U.S. and EU5, plus a substantial addressable market in other regions, including the Gulf Council countries, or GCC, where about 70,000 patients live with the condition. Sickle cell disease is likewise concentrated in the U.S. and the GCC region. That shared footprint in certain geographies gives us a chance to build on our thalassemia commercial work to speed up and bolster the upcoming sickle cell disease launch; with that, I'll hand the call over to Cecilia.

Cecilia Jones

executive
#5

Thank you, Tsveta. You can find our financial results for the second quarter of 2023 in the press release that went out this morning, and additional details will appear in our Form 10-Q, set to be submitted later today. I want to spend a moment giving some background and calling out a handful of items. Net revenue for PYRUKYND in the second quarter of 2023 came to $6.7 million, which is $1.1 million higher than in Q1 2023. Because PYRUKYND is the first treatment available for this ultra-rare adult PKD patient population, we are still collecting data and insights regarding how the launch is progressing, so we will not offer guidance right now. Our expectation remains that the trajectory toward peak will be slow and steady. In line with other rare disease launches, growth to net should land somewhere in the 10%-20% range each year. Cost of sales during the quarter totaled $1.1 million. Now turning to expenses and the balance sheet. R&D spending reached $68.9 million in the second quarter, which is $5.6 million lower than the second quarter of 2022. That reduction came mainly from lower workforce-related expenses resulting from a smaller headcount tied to how our research organization evolved during 2022. SG&A expenses totaled $30.4 million in the second quarter, up $2.1 million versus the second quarter of 2022; the main driver there was higher stock-based compensation expense. Keep in mind that the Tyvaso royalty has come to an end, following the sale of a right to 5% royalties on U.S. net sales of Tyvaso to Sagard in October 2022. Through the divestiture of our oncology business to Servier, we kept rights to a potential $200 million milestone tied to FDA approval of vorasidenib plus 15% royalties on potential U.S. net sales. We closed the quarter holding roughly $947 million in cash, cash equivalents, and marketable securities. We anticipate that this pattern, along with expected product revenue, interest income, and the possible vorasidenib milestone, will allow the company to cover our operating expenses and capital expenditures across multiple value-creating milestones and at least into 2026. This guidance excludes cash inflows from possible royalties on vorasidenib, from commercializing mitapivat outside the U.S. via one or more partnerships, or from other potential strategic business or financial agreements; we are enthusiastic about our potential near-term PYRUKYND launches and still anticipate peak sales of $200 million-$225 million for PKD in the U.S. and $1 billion for worldwide revenues for PKD and thalassemia combined. We stay committed to creating shareholder value, including by proactively managing our cost base and taking a disciplined approach to cash allocation as we get ready to support the potential additional launches of PYRUKYND and keep making strategic investments to advance and grow our pipeline, all of which affects our timing to profitability. As a result of the considerable momentum we've built by carrying out our development plans, and with more possible milestones that could create value coming up soon, I'm confident our solid balance sheet will let us move forward from a position of strength as we keep seeking ways to generate shareholder value. At this point I'll hand the call back to Brian so he can give his closing remarks.

Brian Goff

executive
#6

Appreciate that, Cecilia. Agios just wrapped up an outstanding quarter. We shared favorable phase II results in sickle cell disease, finished enrolling participants across 3 clinical trials, brought in through licensing a strong program from outside that could reshape how a rare blood disorder with substantial unmet need is treated, and we're still building up our commercial strengths to back upcoming launches. Across our PK activator pipeline — the best in the industry — the information we keep producing stays reliable and persuasive, and we're steadily moving forward on our Agios vision: creating a well-established hematology franchise whose approvals cover 3 hemolytic anemias, plus a broader portfolio driven by business development and by pushing our in-house pipeline ahead, all matching our deep roots in rare disease. As we've always done, we'll keep working to be careful guardians of our balance sheet and to weigh significant chances to create value. Last, I want to express gratitude to each of our team members for the effort and commitment they bring to our goal of changing life for people who have rare diseases, and to every one of our collaborators — physicians, patients, caregivers, and those taking part in our clinical development efforts; now let's take questions.

Greg Harrison

analyst
#7

Hey there, morning. I appreciate you fielding this, and congratulations on every one of the updates. First, I'm curious which considerations pushed you toward the choice to license the PV therapy from Alnylam? Does this serve as a template for upcoming business development when it comes to development stage, and having the potential where you could layer in your own know-how and add value? Should we think of this asset as broadly useful across the whole PV population, or, or would it lean toward one particular group of patients?

Brian Goff

executive
#8

Sure thing. Well, morning to you, Greg, and many thanks for that. Yes, it's been a terrific quarter, and I'm glad to offer a few remarks regarding the transaction we made public this morning. This is, polycythemia vera represents a sizable market. In our view it's ready for both disruption and expansion. As I mentioned in my remarks, you know, if you simply consider the current standard of care, that's phlebotomy. For us, that's simply a wonderful chance to do what we excel at, which is to reinvent how these rare diseases get treated and deliver possible disease-modifying therapies to these patients; we're genuinely thrilled about this specific TMPRSS6 asset from Alnylam. It aligns extremely well with our disciplined BD criteria, and it extends our core capabilities, that's spanning our scientific expertise, our development capabilities, our commercial capabilities. If you consider the BD criteria we've discussed so many times, it ticks every box. This is a rare disease. It has transformational potential for patients; we see a chance for early de-risking, which we've discussed often as a sweet spot for us. We believe there's a clear regulatory pathway, and in the end, this will be value-creating, that's our strong belief; it originates from the Alnylam, you know, world-class RNAi platform, we also hold strong conviction in the probability of success based on the data generated to date. We're thrilled about this. I suppose, regarding your question of where we head next for clinical development, I think, and I'll, I'll ask Sarah whether she wants to comment, but it's a bit too soon for us to pin down the target product profile specifically. We have many options. We'll be examining efficacy dimensions, speed of action, for the product itself for patients, safety profile, and of course, convenience. All of those remain in play, but given the stage of development, we're just gonna pause and bring the asset in, really examine it deeply for where, where we can put our development expertise in motion, and then we'll provide updates accordingly. The final thing I'll mention regarding your point about, is this a theme of the sorts of BD deals and so forth going forward? We retain optionality for a range of different BD deals; this one, in particular, really, as I said, ticked every box, and so we were eager to bring it in, but we'll, we'll retain our disciplined BD criteria going forward. Sarah, anything you wanted to add?

Sarah Gheuens

executive
#9

Just to mention that, you know, this has us really enthusiastic. Naturally, as soon as we proceed with the program and gain additional specifics regarding our clinical development program, we will always be aiming to bring value to patients and achieve a significant difference through the development program, and execution on the program is something you can count on as well.

Brian Goff

executive
#10

We are excited to do that. Thanks, Greg.

Greg Harrison

analyst
#11

That's great, that helps. Thank you.

Gregory Renza

analyst
#12

Wonderful. Good morning to you, Brian, and to the whole team. Congratulations on how far things have come, and I appreciate you taking my questions.

Brian Goff

executive
#13

Of course.

Gregory Renza

analyst
#14

Perhaps only a few brief questions from my side. To expand on the in-license Alnylam asset, it might be useful to simply hear what you and Sarah think, specifically regarding the preclinical data so far. Of course, other parties are investigating TMPRSS6 manipulation, and I'm just wondering how you believe this asset might stand apart or be positioned favorably when you review the data that exists up to now. Second, it's excellent to see the dose chosen for the phase III and Sickle. I'm just wondering about the reasoning, when you examined all the data accumulated in the several weeks following the top line and took the step toward 100 mg. Many thanks, and congratulations once more.

Brian Goff

executive
#15

Hey, thank you very much, Greg, and I will pass this along to Sarah for both of those questions.

Sarah Gheuens

executive
#16

Yes, thank you. Regarding the preclinical results, in vivo proof of concept has been shown in non-human primates, along with a very favorable safety profile and really good knockdown of the target that was observed. We have a lot of confidence in that. As we said before, we're quite eager to begin the IND-enabling studies and the CDP, and to give more detail on that as we make progress. I think in our case, yes, other companies are also pursuing this target. As Brian mentioned, this is a huge market. Differentiation is going to come down to efficacy, safety, how it's administered, and how often it's administered. We think our CDP will be able to deliver what the market requires. Yes, again, we're very excited to get started on this. On your second question about the phase III dose selection for sickle cell disease, clearly, we're very excited. We're very excited about the phase II data, and we're very lucky that both doses showed a favorable benefit-risk profile; we had pre-specified criteria in the protocol, the team has now had time to review all of the data, we followed that framework and chose 100 milligrams. We haven't disclosed additional details about the data. We noted that we've submitted the abstract to ASH, so we're now waiting for the outcome of that, and then we hope to be able to share all of that detail at that conference.

Brian Goff

executive
#17

Greg, I might simply add to that as well, noting that any chance to express how proud I am of Sarah and everyone in her R&D group is something I welcome. What we have here is simply a superb illustration of the operational excellence within this organization, along with how efficiently the RISE UP phase II/III trial was designed, plus the reality that we had both doses ready to go. Seeing that each dose worked was a thrill for us, and with the 100-milligram dose now in hand, being able to move forward during the 4th quarter by dosing the 1st patient in the phase III trial strikes me as, you know, once again simply evidence of excellence and something the whole organization can genuinely be proud of.

Gregory Renza

analyst
#18

Of course. I appreciate it, Brian, and thanks as well, Sarah.

Brian Goff

executive
#19

Sure thing. Many thanks.

Divya Rao

analyst
#20

Hello, everybody. We appreciate you answering our question, and congratulations on this quarter. Divya here, calling from Cowen. We have just a couple of items; we're simply wondering, when it comes to the MDS trial, what is your definition of success, or how do you go about defining it? I'm aware that a number of other mechanisms are being explored in this area. Would you consider those to be rivals, or do you instead view them as chances, perhaps, to create combinations involving AG-946? And then I've got a follow-up question.

Brian Goff

executive
#21

Yes. Thank you, Divya. To begin, I'll simply note that, just like with every one of the therapeutic areas we concentrate on, our mechanism of action is quite distinct, involving pyruvate kinase activation. And naturally, regarding the question about low-risk MDS, this concerns our other PK activator, AG-946, and I'm sure Sarah is keen to discuss what we're waiting for when it comes to the phase IIa data.

Sarah Gheuens

executive
#22

Yeah, thank you for bringing that up. Regarding the MDS program, I'd like to point out once more that our team has performed incredibly well when it comes to enrolling patients in that phase IIa study. On top of that, it really shows how eager the investigators are about this mechanism of action for people with MDS. We haven't yet shared the framework for MDS that would define what counts as success, but since this is a phase IIa trial, we're genuinely seeking an efficacy signal along with acceptable safety. If those things show up, our setup positions us to advance quickly into a phase IIb, where we'd conduct proper dose finding. This market is genuinely changing, and I believe that demonstrates it's also a space ready for transformation; we're confident that because of this highly differentiated mechanism of action — one that others aren't currently studying or haven't moved as far along with — we're truly positioned to succeed there too. Something that shouldn't be overlooked is that our treatment is an oral therapy as well, offering ease of use for a patient group that tends to be older.

Divya Rao

analyst
#23

That's quite useful. I have one brief question about the sickle cell program. Would you remind us whether the powering assumption for the phase III trial has been disclosed? Has the 100-milligram dose been talked about with the FDA, or does it mostly come from your own internal discussion and review of the data?

Sarah Gheuens

executive
#24

Regarding the sickle cell disease program, the 100 milligram dose, at this point that is the internal framework we've used along with all the data we've evaluated. We're quite enthusiastic about the end of phase II meeting with the FDA. We're always eager for the constructive dialogue we share. It's always, it's always wonderful, since I genuinely feel we all want the same outcome, correct? Across every one of our programs, we're truly aiming to deliver medications with a favorable benefit risk that can bring change to patients. We're consistently very happy with the constructive dialogue we have; as for the powering assumptions, clearly the phase III has a far larger sample size than the phase II; we have two endpoints there. For the primary endpoint, the hemoglobin endpoint, we rely on and use our internal data for all the statistical underpinnings. Then for the VOCs, clearly, we've been examining other programs to make powering assumptions there and are seeking to make a meaningful change on VOCs for patients.

Brian Goff

executive
#25

Thanks.

Anu Midha

analyst
#26

Morning. Anu Midha here, on behalf of Salveen. We have a single question regarding the licensing deal with Alnylam. Since siRNA is such a new modality for Agios, why are you confident about the clinical development process? Thanks.

Sarah Gheuens

executive
#27

Appreciate the question. What gives us confidence, I'd say, is that we possess in-house know-how from people who've worked with this modality, and with plenty of others too. It's not as though this compound or modality is unfamiliar to Agios staff, even if it is new to Agios as a company. So we're eager to apply that internal knowledge. And when it comes to endpoint, patient populations, all of that, I really believe it falls squarely within our expertise in hematology drug development, so we're excited to bring those capabilities to bear there too.

Anu Midha

analyst
#28

Thanks.

Andrew Berens

analyst
#29

Hey, thank you. Congratulations on the transaction. My questions also relate to the MDS program. Could you provide some perspective on how you view the PKR class within MDS? I believe luspatercept is actually performing quite strongly in that indication, with revenue exceeding $700 million in a subpopulation. Could you share the physiological basis for the PKR class in MDS, and also how you anticipate it might be positioned against the EPO agents? Finally, I realize it’s early, but how do you think EPO agent use in that disease would hypothetically affect pricing power?

Brian Goff

executive
#30

Yes. Andy, many thanks for the question. I’ll begin by underscoring what you just mentioned; we see it as a highly appealing opportunity given the existing incumbents and the advances they are achieving. The patient population, as shown on one of our slides, you know, we count as 75,000 to 80,000 patients across the U.S. and EU5. This is another disease that is ready for disruption and entering with PK activation, a very distinct mechanism of action. As Sarah has pointed out a few times already, in addition to all of that, as an oral small molecule, we believe it has considerable potential to be differentiated, but naturally, we’ll be guided by the 2A data. Would you like to add anything, Sarah?

Sarah Gheuens

executive
#31

Okay, regarding the reason we think PK activation could be effective in MDS — there really are similarities linking MDS and thalassemia, and we've clearly made solid progress in thalassemia at this point; that's one factor; beyond that, the glycolytic pathway gets disrupted in MDS patients on several levels, and we think we're able to affect that too. You see disruptions in the hexokinase to pyruvate kinase ratio. Then there's the reality that an acquired PK deficiency is common among MDS patients. A whole host of factors support our belief that activating PK might deliver benefit; we've put out published data on this at EHA, at ASH, and ideally there's more coming at ASH. We're genuinely thrilled about the evidence we keep accumulating in this disease.

Brian Goff

executive
#32

Andy, one more thing I want to mention: our team has substantial depth in a lot of the therapeutic areas we're targeting, and with us right now is Tsveta Milanova, our Chief Commercial Officer, who's actually been deeply engaged in this space. So of course it's early — we're examining phase IIa data. Past that point, Tsveta can bring a great deal of perspective and know-how, not only regarding the product's commercial profile but also, to address what you raised, around pricing later on and how we get the most out of value creation. We believe we're extremely well positioned, and we can hardly wait for this milestone coming up by year-end.

Andrew Berens

analyst
#33

Great. Thanks very much.

Brian Goff

executive
#34

You bet. Thank you.

Tess Romero

analyst
#35

Good morning, Brian, and everyone else. Thanks for letting us ask something. Today I wanted to bring up a business-related topic. Regarding PYRUKYND, as the number of people taking the drug increases, I'm simply trying to understand how you view the pattern for adding new patients. From what I gather, the rate of patients stopping seems quite modest. Do you believe this pace of roughly 10 sequential net patient additions, which is what you've observed over the past 2 quarters, is the proper lens through which to view the launch moving ahead, or might it be something that speeds up more because of certain efforts around analytics and similar things? Many thanks.

Brian Goff

executive
#36

Yes, thank you. Thank you, Tess. Tsveta is very excited that someone asked about commercial, so I will hand it over to her for her thoughts.

Cecilia Jones

executive
#37

Hello, Tess, and good morning. Like you mentioned, we're still achieving milestones with the launch. The key point is that PYRUKYND's real-world performance remains impressive, particularly regarding persistency, favorable feedback from providers, and backing from payers. That said, we recognize PKD is an ultra-rare condition, and as we noted during our opening comments, we anticipate that adoption will keep happening gradually and consistently. Some quarter-to-quarter fluctuation is likely, and our focus stays sharply on pinpointing the appropriate providers—those who probably have patients dealing with PKD deficiency and individuals suited for PYRUKYND, whether right now or possibly later on. That's why our work in data and analytics goes on, to back our team while we keep carrying out field operations. Crucially, every capability we're developing at present forms a solid base for us as we keep exploring ahead and considering possible upcoming indications, plus extensions for PYRUKYND, including thalassemia too.

Brian Goff

executive
#38

Yeah, what I'd simply say in addition, Tess, is that this launch is quite one of a kind; it sits pretty far along the ultra-rare spectrum, and while we're accumulating insights from it, I would view it as gradual, consistent expansion, and we always advise being somewhat cautious regarding quarter-over-quarter, since it's going to be uneven for a good while. Tsveta and the team keep achieving things we feel a great deal of pride in.

Tess Romero

analyst
#39

Great. If I could just fit in one more commercial question there. So, with these dynamics in play, how are you thinking about giving longer-term PYRUKYND guidance? Do you feel like you might be in a spot to do that once we sort of wrap up 2023 and move into the following year?

Brian Goff

executive
#40

Sure. Thanks. Cecilia, do you want to handle that?

Tsveta Milanova

executive
#41

Sure, I can handle that one. Like we said earlier, what we're dealing with here is an initial treatment for an extremely rare condition. We keep gaining knowledge from the data and what we're seeing. Right now, we aren't going to provide any guidance. A moment for that will arrive. We'll keep assessing when that moment is appropriate.

Brian Goff

executive
#42

Right, so as we've discussed before, our anchor point is peak sales of $200 million to $225 million in the U.S. — that's the figure we have confidence in. We'd like to accumulate additional quarters before providing revenue guidance for PKD. Naturally, from a broader perspective, what matters most for us is that we're getting close to the readout of the thalassemia data. That represents a substantially bigger launch, with potential in 2025. We might find ourselves in a position where we begin considering collective guidance across multiple launches.

Tess Romero

analyst
#43

Excellent, we really appreciate you answering our inquiry.

Brian Goff

executive
#44

Of course, Tess, thank you.

Danielle Brill

analyst
#45

Morning, everyone, and thanks a lot for taking the question. I've got something to ask about that in-licensed asset as well. I'm aware that antibodies aimed at TMPRSS6 are also being developed. Could you say more about the reasons siRNA might be the better modality here? Is the appeal simply a dosing schedule that's more convenient, or might there also be an efficacy edge? Thanks.

Brian Goff

executive
#46

Thanks very much, Danielle, for raising that. As I mentioned before, we see potentially several ways to stand apart. In our view, TMPRSS6 is by now a well-established pathway. Put very simply, knocking down TMPRSS6 by 90% produces an uplift effect on hepcidin, and that decreases iron, which in the end lowers the production of red blood cells. That chain running through that mechanism — after all our diligence, we're very confident in it. Like I said, I believe there will be chances for efficacy. Safety, naturally, will be... You know, when you consider some of what's currently available therapeutically for patients, that's one area with plenty of room for improvement. It might also turn out to be a meaningful convenience opportunity, since siRNA, classically, and especially coming from the Alnylam platform, has demonstrated that this mechanism has delivered benefit to patients with a lower interval of treatment. We're gonna examine all of that; it's very early, and our IND-enabling studies will begin this year, after which we'll report out our progress accordingly.

Danielle Brill

analyst
#47

Thanks so much.

Brian Goff

executive
#48

Sure. Thank you.

Brian Goff

executive
#49

Okay, thanks so much, everyone, for joining us on today’s call, and naturally, for the ongoing interest you’ve shown in Agios. As you were told earlier today, we’re genuinely energized by the huge strides we keep achieving throughout our portfolio. We have confidence in our ability to produce meaningful long-term value for patients as well as shareholders. Thanks again so much, and we can’t wait to talk with you before long.

Operator

operator
#50

That brings us to the end of this call. We appreciate you joining us. You're free to hang up now. Wishing all of you a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.